RESUMEN
Untwisting contributes to left ventricular filling through suction generation. We sought to investigate diastolic function and untwisting dynamics in different forms of left ventricular hypertrophy: in athlete's heart and hypertrophic cardiomyopathy. Elite athletes in kayaking, canoeing and rowing (n=28), patients with hypertrophic cardiomyopathy (HCM, n=15) and healthy sedentary volunteers (n=13) were compared. Left ventricular volumes, wall thickness-to-volume ratio were assessed by cardiac MRI. Following conventional and tissue Doppler measurements, untwist and untwist rate were determined by speckle tracking echocardiography. Wall thickness-to-volume ratio describing remodelling was significantly higher in HCM, but similar in athletes and controls (athlete vs. HCM vs. control: 0.107±0.019 vs. 0.271±0.091 vs. 0.104±0.012 mm×m²/ml, mean±SD, p<0.001). Mitral lateral annulus e' velocity referred to diastolic dysfunction in HCM (15.3±3.6 vs. 7.9±3.3 vs. 15.0±3.0 cm/s, p<0.01). At time point of mitral valve opening, untwist and untwist rate were significantly different: the highest values were measured in athletes, while the lowest were found in HCM (untwist: 51.3±19.1 vs. 11.6±10.4 vs. 35.9±16.3%; untwist rate: -32.5±13.0 vs. -10.6±10.8 vs. -23.0±7.7°/s, p<0.05). Untwisting correlated with E/A, e' and E/e'. Athlete's heart is characterized by increased untwist and untwist rate, which can aid diastolic function. Evaluation of untwisting dynamics may help to distinguish pathological hypertrophy.
Asunto(s)
Diástole , Hipertrofia Ventricular Izquierda/fisiopatología , Deportes/fisiología , Función Ventricular , Ventrículos Cardíacos/diagnóstico por imagen , Hemodinámica , Humanos , Hipertrofia Ventricular Izquierda/diagnóstico por imagen , Imagen por Resonancia Magnética , Acondicionamiento Físico Humano , UltrasonografíaRESUMEN
Meta-[123I]iodobenzylguanidine (123I-MIBG) is currently used to assess myocardial sympathetic innervation by single photon emission tomography (SPET). In recent studies, an enhanced cardiac uptake of 123I-MIBG with high specific activity has been reported, suggesting the clinical potential of no-carrier-added (n.c.a.) 123I-MIBG in the assessment of abnormalities in cardiac sympathetic function. This paper describes the preparation of n.c.a. 123I-MIBG by non-isotopic Cu(I)-assisted [123I]iododebromination and by [123I]iododestannylation, both resulting in n.c.a. 123I-MIBG with radiochemical yields of 88 +/- 6% and high specific activity (> or = 6.3 TBq.mumol-1) in a total synthesis time of less than 50 min. The diagnostic potential of n.c.a. 123I-MIBG (> 6.3 TBq.mumol-1) was studied in 13 patients (nine patients with malignant ventricular arrhythmias and four patients suspected of phaeochromocytoma) and compared to commercial 123I-MIBG (approximately 75 MBq.mumol-1) using a dual-headed SPET camera (MULTISPECT II). High specific activity results in higher 123I-MIBG uptake in the heart and in the liver in all patients. The calculated heart-to-lung and heart-to-liver count ratios 4.5 h post-injection increased by 22 +/- 6% and 10 +/- 5% with n.c.a. 123I-MIBG compared to commercial 123I-MIBG respectively. In contrast, no significant correlation between the specific activity of 123I-MIBG and lung uptake could be established in this study. Analysis of radioactivity in blood after the intravenous injection of n.c.a. and commercially available 123I-MIBG showed an initial rapid clearance of radioactivity from blood, followed by a plateau from 60 min onwards. Within the first 24 h, more than 85% of the plasma activity was unchanged 123I-MIBG. The free 123I-iodide concentration determined 24 h post-injection was 2 +/- 1% with commercial 123I-MIBG and 3 +/- 2% with n.c.a. 123I-MIBG. In conclusion, the results of this investigation indicate that n.c.a. 123I-MIBG is a promising clinical tool for imaging myocardial sympathetic dysfunction by SPET. High specific activity n.c.a. 123I-MIBG can now be prepared by simple one-step methods giving high radiochemical yields and high purity suitable for clinical application. This encourages the further clinical validation of n.c.a. 123I-MIBG on a large scale.
Asunto(s)
3-Yodobencilguanidina , Arritmias Cardíacas/diagnóstico por imagen , Radioisótopos de Yodo , Radiofármacos , Anciano , Arritmias Cardíacas/fisiopatología , Estudios de Evaluación como Asunto , Femenino , Humanos , Hígado/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
As the healthcare industry becomes more involved in joint venture activity, it must become more concerned with the possibility of illegal remuneration. Illegal remuneration, or the soliciting, receiving, offering, or paying of remuneration in return for the referral of patients or generation of business, is treated very seriously by HHS and the courts. Therefore, joint ventures must be constructed to avoid the danger areas as much as possible, or at least, minimize the risk.
Asunto(s)
Crimen/legislación & jurisprudencia , Administración Financiera de Hospitales/legislación & jurisprudencia , Administración Financiera/legislación & jurisprudencia , Fraude/legislación & jurisprudencia , Administración Hospitalaria/legislación & jurisprudencia , Convenios Médico-Hospital/legislación & jurisprudencia , Comercio , Estados Unidos , United States Dept. of Health and Human ServicesAsunto(s)
Neoplasias Abdominales/diagnóstico por imagen , Huesos/diagnóstico por imagen , Neuroblastoma/diagnóstico por imagen , 3-Yodobencilguanidina , Abdomen/diagnóstico por imagen , Difosfonatos , Humanos , Lactante , Masculino , Compuestos de Organotecnecio , Radiografía Abdominal , Radiografía Torácica , Cintigrafía , Radiofármacos , UltrasonografíaRESUMEN
Because the coincidence of hyperthyroidism and pregnancy is rare, there is come uncertainty in the management of these patients. In order to avoid complications during the course of pregnancy, it is important to know--besides etiology and pathogenesis--the particularities in diagnosis and start of the appropriate therapy in time.
Asunto(s)
Hipertiroidismo/diagnóstico , Complicaciones del Embarazo/diagnóstico , Antitiroideos/administración & dosificación , Antitiroideos/efectos adversos , Femenino , Edad Gestacional , Enfermedad de Graves/diagnóstico , Enfermedad de Graves/etiología , Enfermedad de Graves/terapia , Humanos , Hipertiroidismo/etiología , Hipertiroidismo/terapia , Recién Nacido , Embarazo , Complicaciones del Embarazo/etiología , Complicaciones del Embarazo/terapia , TiroidectomíaRESUMEN
The trityl group was recently introduced for the protection of the side chain carboxamide function of asparagine and glutamine. The 4-methyltrityl (Mtt) group, a structural modification of trityl, is presented here and allows more rapid cleavage from the protected peptides. Procedures for the introduction of the group and comparative cleavage reactions are also presented.
Asunto(s)
Asparagina/química , Glicina/química , Péptidos/química , Compuestos de Tritilo/química , Secuencia de Aminoácidos , Datos de Secuencia MolecularRESUMEN
This paper presents a reevaluation of the synthesis and properties of Fmoc-His(3-Bum)-OH regarding its application in SPPS with minimal racemization of histidine residues during coupling and esterification reactions. By-product formation during the deprotection of the test peptides could be significantly reduced by scavenging the concomitantly formed HCHO, e.g. with methoxyamine.
Asunto(s)
Aminoácidos/química , Aminoácidos/síntesis química , Fluorenos/química , Fluorenos/síntesis química , Histidina/síntesis química , Biosíntesis de Péptidos , Cromatografía Líquida de Alta Presión , Fluorenos/farmacología , Histidina/análogos & derivados , Histidina/química , Histidina/farmacología , Espectroscopía de Resonancia Magnética , Modelos Químicos , Espectrometría de Masa por Ionización de ElectrosprayRESUMEN
The sequence dependence of base-catalysed aspartmide formation during Fmoc-based SPPS was systematically studied employing the peptide models H-Val-Lys-Asp-Xaa-Tyr-Ile-OH. The extent of formation of aspartimide and related by-products was determined by RP-HPLC. Considerable amounts of by-products were formed in the case of Xaa = Asp(OtBu), Arg(Pbf), Asn(Mtt), Cys(Acm) and unprotected Thr. Aspartimide formation could be diminished by incorporation of Asp(OMpe) or by employing milder methods for Fmoc cleavage, e.g. hexamethyleneimine/N-methylpyrrolidine/HOBt/NMP/DMSO 4:50:4:71:71 (v/v/w/v/v).
Asunto(s)
Aminoácidos/química , Ácido Aspártico/análogos & derivados , Ácido Aspártico/química , Fluorenos/química , Compuestos Bicíclicos Heterocíclicos con Puentes/química , Cromatografía Líquida de Alta Presión , Biosíntesis de Péptidos , Péptidos/química , Piperidinas/químicaRESUMEN
A variety of Asp beta-carboxy protecting groups, Hmb backbone protection and a range of Fmoc cleavage protocols have been employed in syntheses of the model hexapeptide H-VKDGYI-OH to investigate the aspartimide problem in more detail. The extent of formation of aspartimide and aspartimide-related by-products was determined by RP-HPLC. This study included three new Fmoc-Asp-OH derivatives: the beta-(4-pyridyl-diphenylmethyl) and beta-(9-phenyl-fluoren-9-yl) esters and also the orthoester Fmoc-beta-(4-methyl-2,6,7-trioxabicyclo[2.2.2]-oct-1-yl)-alanine. 3-Methylpent-3-yl protection of the Asp side chain resulted in significant improvements with respect to aspartimide formation. Complete suppression was achieved using the combination OtBu side chain protection and Hmb backbone protection for the preceding Gly residue.